CXCL10 and neoplasm: In renal cell carcinoma, endogenous CXCL9 was closely implicated in the antitumor effects that were produced by IL‐2 64 and IL‐12 (also producing CXCL10) 65 by inhibiting tumor angiogenesis and infiltration of CD8+ T lymphocytes, respectively.